{"id":"bhv-7000","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Musculoskeletal pain"},{"rate":"null","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL384200","moleculeType":"Small molecule","molecularWeight":"858.34"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BHV-7000 works by blocking the action of calcitonin gene-related peptide (CGRP) at its receptor, which is involved in the transmission of pain signals. This mechanism is thought to be beneficial in the treatment of migraine and other headache disorders.","oneSentence":"BHV-7000 is a calcitonin gene-related peptide receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:23:31.847Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Migraine prevention"}]},"trialDetails":[{"nctId":"NCT06425159","phase":"PHASE2, PHASE3","title":"A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures","status":"TERMINATED","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-06-20","conditions":"Generalized Epilepsy","enrollment":27},{"nctId":"NCT06309966","phase":"PHASE2, PHASE3","title":"Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy","status":"RECRUITING","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-05-13","conditions":"Focal Epilepsy","enrollment":390},{"nctId":"NCT06132893","phase":"PHASE2, PHASE3","title":"A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy","status":"RECRUITING","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-03-14","conditions":"Focal Epilepsy","enrollment":390},{"nctId":"NCT07125261","phase":"PHASE1","title":"BHV-7000 Responsive Neurostimulation System (RNS) Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2025-10-07","conditions":"Epilepsy, Seizures","enrollment":5},{"nctId":"NCT06443463","phase":"PHASE2","title":"Long-term Safety and Tolerability of BHV-7000","status":"ENROLLING_BY_INVITATION","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-07-30","conditions":"Focal Epilepsy","enrollment":660},{"nctId":"NCT07262268","phase":"PHASE1","title":"A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia","status":"ENROLLING_BY_INVITATION","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2026-01-15","conditions":"Familial Erythromelalgia","enrollment":5},{"nctId":"NCT06419608","phase":"PHASE2","title":"Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression","status":"COMPLETED","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-05-28","conditions":"Major Depressive Disorder","enrollment":336},{"nctId":"NCT06419582","phase":"PHASE2, PHASE3","title":"BHV-7000 Acute Treatment of Bipolar Mania","status":"COMPLETED","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-05-28","conditions":"Bipolar Disorder","enrollment":274},{"nctId":"NCT06423794","phase":"PHASE2","title":"BHV-7000 Open-Label Extension Bipolar Mania Study","status":"TERMINATED","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-06-24","conditions":"Bipolar Disorder","enrollment":94},{"nctId":"NCT06423781","phase":"PHASE2","title":"Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)","status":"ENROLLING_BY_INVITATION","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-08-01","conditions":"Major Depressive Disorder","enrollment":480}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["opakalim"],"phase":"phase_2","status":"active","brandName":"BHV-7000","genericName":"BHV-7000","companyName":"Biohaven Therapeutics Ltd.","companyId":"biohaven-therapeutics-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BHV-7000 is a calcitonin gene-related peptide receptor antagonist. Used for Migraine prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}